聖湘生物(688289.SH):以合計2.5億元取得真邁生物約14.77%的股權
格隆匯6月21日丨聖湘生物(688289.SH)公吿,公司與深圳市真邁生物科技有限公司(“真邁生物”)及其股東深圳市中科達瑞基因科技有限公司、深圳閃士多實業有限公司、深圳市萬力拓電子商務科技有限公司簽訂《投資協議》,公司通過股權轉讓、認繳新增註冊資本的方式,以合計2.5億元的價格取得真邁生物14.767273%的股權,溢價率約為22倍,真邁生物專注於基因測序產業上游設備和試劑的研發製造。
通過此次交易,聖湘生物與真邁生物將達成戰略合作,雙方可在知識產權、人才團隊、技術平台等方面充分發揮協同效應,優勢互補,從而在基因測序、PCR等分子診斷領域進行更深入地研發及探索,充分挖掘其可持續發展的潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.